Table 3.
Subgroup | No. studies | No. patients | Fixed-effects model | Heterogeneity | ||
---|---|---|---|---|---|---|
HR (95% CI) | P-value | I2 (%) | PH-value | |||
Tumor Site | ||||||
PCa | 2 | 558 | 2.42 (1.44-4.07) | 0.001 | 0 | 0.425 |
RCC | 6 | 4720 | 2.99 (2.29-3.89) | <0.001 | 0 | 0.716 |
UTUC | 4 | 1050 | 2.43 (1.84-3.20) | <0.001 | 0 | 0.807 |
Ethnicity | ||||||
Asian | 7 | 4645 | 2.63 (2.14-3.22) | <0.001 | 0 | 0.600 |
Caucasian | 5 | 1683 | 2.83 (1.92-4.17) | <0.001 | 0 | 0.894 |
Cut-off value | ||||||
<350mg/dl | 4 | 2055 | 2.65(1.74-4.03) | <0.001 | 0 | 0.743 |
≥350mg/dl | 8 | 4273 | 2.67(2.19-3.26) | <0.001 | 0 | 0.716 |
Overall | 12 | 6328 | 2.67 (2.23-3.19) | <0.001 | 0 | 0.888 |
CSS: cancer-specific survival, HR: hazard ratio, CI: confidence interval, PH : P for heterogeneity, PCa: prostate cancer, RCC: renal cell carcinoma, UTUC: upper tract urothelial carcinoma.